What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Antibiotics/Anti-infectives

Stecix-O DS

Cefixime + Ofloxacin Ds

Pack: 30ML
Format: With Carton

MRP₹92.81

A high-potency, dual-action antibacterial suspension engineered for the intensive management of severe or multi-drug resistant pediatric infections. STECIX-O DS combines a third-generation cephalosporin with a powerful fluoroquinolone to provide a massive spectrum of coverage against tough respiratory, enteric, and urinary pathogens.

About The Product

Key Benefits

Synergistic Dual-Antibiotic Power

STECIX-O DS utilizes the combined strength of Cefixime and Ofloxacin. While Cefixime destroys the bacterial cell wall, Ofloxacin penetrates the bacteria to inhibit DNA gyrase, preventing the pathogen from replicating. This dual-attack mechanism ensures that even bacteria resistant to a single antibiotic are effectively eliminated.

Gold-Standard Treatment for Typhoid Fever

This combination is highly effective for the clinical management of enteric (Typhoid) fever. By targeting Salmonella typhi through two different biological pathways, STECIX-O DS ensures a faster reduction in high-grade fever and significantly lowers the risk of carrier states or disease relapse in children.

Intensive Respiratory and Sinus Coverage

STECIX-O DS is indicated for complicated respiratory tract infections, including severe bronchitis and resistant sinusitis. Its superior tissue penetration allows the medication to reach deep into the lungs and sinus cavities, clearing persistent infections that have failed to respond to primary antibiotic therapy.

Management of Complicated Urinary Tract Infections

The high concentration of active ingredients in the "DS" (Double Strength) formulation makes it an excellent choice for treating pediatric UTIs. It rapidly eliminates Gram-negative bacteria in the urinary tract, relieving painful urination and preventing the infection from spreading to the kidneys.

Overcoming Bacterial Resistance

By using two different classes of antibiotics, STECIX-O DS prevents the bacteria from developing "escape" mechanisms. This makes it a critical tool in the pediatric clinical setting for treating community-acquired infections where resistance to standard penicillins or older cephalosporins is suspected.

Optimized Pediatric Absorption

The suspension is formulated for rapid gastrointestinal absorption, ensuring that therapeutic levels of both Cefixime and Ofloxacin reach the bloodstream quickly. The Double Strength (DS) concentration allows for a smaller volume per dose, making it easier for children to complete their full course of treatment.

Indication Severe Typhoid (Enteric) Fever, Complicated Urinary Tract Infections (UTIs), Resistant Acute Otitis Media, Chronic Bronchitis and Pneumonia, Skin and Soft Tissue Infections, Post-Surgical Prophylaxis.

Indications

Severe Typhoid (Enteric) Fever
Complicated Urinary Tract Infections (UTIs)
Resistant Acute Otitis Media
Chronic Bronchitis and Pneumonia
Skin and Soft Tissue Infections
Post-Surgical Prophylaxis.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

Stecix-O DS